Cellerant Therapeutics is a privately-held, clinical-stage biotechnology company with a portfolio of novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics. Cellerant's lead product, CLT-008, is a myeloid progenitor cell therapy currently in Phase 2 clinical development in patients with acute myeloid leukemia (AML). The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for AML, multiple myeloma and myelodysplastic syndrome.
Cellerant's Press Releases
August 22, 2017
Cellerant awarded a grant from the California Institute for Regenerative Medicine (CIRM)
October 11, 2016
Cellerant presents preclinical data showing promise of a novel differntiated target on leukemic stem cells
September 26, 2016
Cellerant Awarded $1.5 million SBIR Contract for Development of Novel Antibody-based Therapeutics Against IL1RAP